Orphazyme
New therapies for the treatment of rare and genetic diseases.
Launch date
Employees
Market cap
AUD7.0m
Enterprise valuation
(AUD3m) (Public information from Aug 2023)
Share price
DKK875 ORPH
Company register number 32266355
Copenhagen Capital Region of Denmark (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | <1m | 5.3m | 3.1m | 5.4m |
| % growth | - | - | - | - | 1700 % | (42 %) | 76 % |
| EBITDA | (19.1m) | (33.7m) | (49.0m) | (88.9m) | (83.9m) | (4.1m) | (1.8m) |
| % EBITDA margin | - | - | - | (30300 %) | (1589 %) | (133 %) | (33 %) |
| Profit | (18.5m) | (33.7m) | (49.4m) | (92.8m) | (92.0m) | 3.8m | (3.8m) |
| % profit margin | - | - | - | (31650 %) | (1742 %) | 124 % | (70 %) |
| EV / revenue | - | - | - | 836.0x | 14.9x | -0.5x | 0.8x |
| EV / EBITDA | -6.8x | -2.0x | -4.2x | -2.8x | -0.9x | 0.4x | -2.4x |
| R&D budget | - | - | 41.8m | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Seed | ||
$20.0m | Series A | ||
N/A | Grant | ||
$24.0m | Series B | ||
€14.0m | Late VC | ||
| N/A | €80.0m Valuation: €240m -30.0x EV/LTM EBITDA | IPO | |
* | N/A | $109m Valuation: $420m -8.6x EV/LTM EBITDA | Post IPO Equity |
* | $12.8m Valuation: $12.8m 2.4x EV/LTM Revenues | Acquisition | |
| Total Funding | AUD91.8m | ||
